Comprehensive Analysis Reveals iPSC Potential in CAR-T Therapy for Cancer, Highlights Key Challenges

September 13, 2026

Research Journal of Pharmacy and Technology India

Overview

A comprehensive review analyzes the therapeutic potential and inherent risks of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) in cancer therapy. Notably, iPSCs hold significant promise as patient-specific and renewable cell sources for CAR-T cell therapy. However, immunological rejection, malignant transformation risks, and stringent regulatory hurdles remain significant barriers to widespread clinical application. MSCs’ tumor-homing capabilities are also highlighted as a promising aspect.

In Depth

Key Findings

A comprehensive review of stem cell applications in cancer therapy meticulously dissects the distinct therapeutic potentials and inherent risks associated with hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). The review particularly emphasizes the immense promise of iPSCs as a patient-specific and renewable cell source for CAR-T cell therapies, attributing this potential to their indefinite proliferative capacity and pluripotency.

Technical and Clinical Details

The review details the established role of HSCs in treating hematological malignancies, while exploring MSCs for their immunomodulatory properties and tumor-homing capabilities, positioning them as potential platforms for cell and gene delivery. For iPSCs, the ability to derive them from somatic cells allows for the genetic engineering of autologous cells, offering an ‘off-the-shelf’ approach for producing CAR-T cells with reduced immunogenicity. However, critical challenges persist for iPSC clinical translation, including immunological rejection, the risk of teratoma formation (malignant transformation) from undifferentiated cells, and off-target effects of gene editing. Overcoming these requires precise differentiation protocols and rigorous quality control measures.

Background and Industry Context

Cancer treatment is rapidly evolving beyond conventional chemotherapy and radiation, with immunotherapies and cell therapies emerging as transformative modalities. CAR-T cell therapy, in particular, has shown dramatic efficacy in certain hematological cancers, but faces hurdles such as high manufacturing costs, personalized production complexity, and severe adverse effects. iPSC-based CAR-T cells offer solutions to some of these challenges by enabling more uniform, scalable, and potentially more affordable therapies. Advances in stem cell research are therefore pivotal in shaping the future of oncology.

Strategic Significance and Outlook

The application of stem cells in cancer therapy will continue to advance, balancing their profound potential with inherent complexities and risks. Key to the progress of iPSC-derived CAR-T cells will be mitigating malignant transformation risks, controlling immunogenicity, and optimizing manufacturing processes. If these challenges are resolved, the future could see widely accessible, effective, and safer cellular therapies for cancer. Regulatory bodies are simultaneously developing frameworks to guide these innovative treatments, striving to balance scientific progress with paramount patient safety.

Source: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-9-70

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.